Connect with us

Cannabis News

Trucking Industry Group Is ‘Deeply Concerned’ About Marijuana Rescheduling’s Potential Impact On Drug Testing For Drivers

Published

2 months ago

on

American truck associations (ATA) say that “very worried” is in drug testing programs.

Sean Duffy Sean Duffy, Dan Horvath, said Dan Horvath. Dan Horvath is capable of achieving the authority and ability to control the transport employees of the marijuana commercial engine (CMV) and security staff “.

Of course, this policy has not yet been prescribed. And while President Donald Trump said he will take a decision about the recently mentioned proposal in the week-Txo protect the reform on the route of the campaign last year – should be seen whether he wants to continue the restoration.

Horvath said that the door “does not have a formal position to legalize or deregulation,” we are very worried about re-programming safety risks, testing the authority and technical requirements for the necessary security staff. “

Concern is a potential guideline for the compulsory federal drug test if they will now be transferred to the Cannabis III Program.

“If so, dot programs to keep programs without cleaning, to maintain marijuana testing authority, and such federal policy changes can be serious consequences for highway safety and national transport network,” letters said. “This risk is not a proven standard, a highly accepted standard before the roadside or before the driver starts working before the vehicle is harder to prevent driving disability.”

“The implications of a gap in the test authority are well documented in the implications of potential security,” Horvath said, pointing to the data The rate of Positive Thc among the driver And research showed the increase in traffic death after state legalization.

“The door has repeatedly transmitted these concerns, and our demand about potential clarity, in the DOT test program, according to the previous administration, both in discussions about formal letters and people”. new According to transport issues.

Horvath also noticed Pete Buttigieg while the Secretary of Transportation has told a conference committee last year Rescheduling would not affect drug testing regulationsAta “never received Answer to our correspondence Explain the basis of this position or explain the details that intend to deal with impacts in the program. “

“The public attention of marijuana policy and marijuana is a federal novelty, we want to effectively coordinate the change in the HHS (Department of Justice) to ensure the authority, tools and technical skills in controlling federal policy.”

Meanwhile, a policy in a couple of companies in the truck industry premiered in April, which sought was approximately 80,000 drivers Positive to marijuana says staff had aggravated Zero-tolerance drug policy below dot.

MARIHUANA Moving III “dot regulations and drug test protocols”, papers, for example, recognizing legal medical use and reducing social stigma, but should not be facilitated.

Dot drug screening program usually uses urinary-based tests, but the report says that Saliva and hair follicle test provides benefits in this standard. It is warned that “there is no extended test today to determine whether a driver is exposed to a drug like THC.”

The Department ended the new test policy in 2023 Allow oral salt drug testing as an alternative to testing based on urine. Late Last last year, critics fell more than half years after the end of the authority, Fixed officials had yet to use the necessary infrastructure to use the new test procedure.

Legislators of Congress Auditions in March The truck industry representatives heard that they called the use of hair follicle tests in the industry. President of the National Transport Safety Commission (NTSB) recommended better education for drivers.

In April, the US Supreme Court A Cannabis company sued for a truck after shooting for a positive THC test He said consuming the CBD product derived from hemp.

Separately, substance abuse and mental health services administration (Samhsa) Official Criticism of a drug testing drug testing “means a drug test” means Canavies use cannabis to do with the nearby impunityA couple of days while avoiding drug test. “

The Transport Industry also recommended the Congress in January If Marijuana is federally restructuring, businesses do not ensure that zero tolerance policies do not need drivers-The key problem of the questionnaire is lacking technology to detect driving handicap.

Report of the 2023 Congress of Congress of Transport, Housing and Urban Development and Related Agencies (Thud), the House Credit Committee “Marijuana impairment measurement measurement is continued to measure the measurement test measurement of sobriety tests to ensure highway security. “

A year earlier in Colorado John Hickenlooper (D) Senin sent the letter to the point Looking for an update in this state of a federal report In the roads that inhibit the development of standardized marijuana deterioration on the roads. The Department Report had to complete Under a large-scale infrastructure bill Then signed by President Joe Biden, but The deadline he reported.

Meanwhile, the National Transport Safety Commission (NTSB) warned Marijuana again program “blind places” to test federally regulated employee tests in security sensitive positions.

On the home committee, then the Dot Secretary mentioned concerns about the door “about the general public” Effects of Highway National System Appeal and Safety Conclusions And his users, “Truck Associations were thrown in a letter to the secretary.

The current federal laws promise to abstain by commercial drivers from cannabis to different types of drug performances, pre-work, random tests.

In June 2022, they found the ATRI survey of the US Licensed Truck Drivers 72.4 percent “release” supports cannabis law and test policies. Another 66.5, 66.5 said Marijuana had to be legalized federally.

Cannabis deforms reforms, while, too The federal civil servant called the “discriminatory” drug test practice around the truck industry.

Fargo Analysis A top well said in 2022 that the main reason for raising costs and staff in the transport sector: marijuana criminalization and As a result, drug testing orders This follows as more states legalize.

Later representative. Earl Blumenoer (or) sent a letter to Motura in 2022, emphasizing that they are policies about the drug testing truck and commercial marijuana useless people cost their work And it helps supply chain problems.

2022 ATRI reports that the impact of cannabis is affected and the impact on motorway security is currently confused, complicating the judgment to correct the problem. A separate 2019 Congress Research Service Report (CRS) It has also been found that evidence of the decline in cannabis is not inclusive.

Read ata’s print Maryhuana rewrite and drug testing followed:

Marijuana is possible with the help of readers. If you are based on journalism to defend cannabis, consider the commitment to Patreon every month.

(Tagstotranslate) highlighted

Related Topics:
Continue Reading

Cannabis News

Opening the doors to standardized cannabis propagation

Published

11 hours ago

on

October 26, 2025

By

Twenty cannabis growers from all over Europe and the world recently gathered in Austria for another industry event: a one-day invitation-only masterclass on cannabis propagation, hosted by Fluence, one of Europe’s largest cannabis clone producers, at the Flowery Field in Vienna.

The day included lectures, live demonstrations and a rare guided tour through a facility that is usually closed to outsiders. “It was a good mix of practice and theory,” says Fluence’s Theo Tekstra. “In the morning we had a theoretical block, then we had an in-depth tour of the tissue culture laboratory and the mother plant and reproduction areas, and in the afternoon a practical workshop. Everyone saw and participated in the whole process.”

© Fluence BioengineeringA cannabis tissue culture clone in the early rooting hardening phase was demonstrated at the Flowery Field hands-on session, demonstrating propagation techniques with Fluence LED lighting.

Historical installation
Flowery Field was founded by Alexander Klima, a former law student who noticed that Austrian regulations discriminated between plants and their uses. In practice, this means that cannabis can be sold as an ornamental plant, as long as it is not harvested for consumption.

What started as a small shop selling houseplants along with cannabis cuttings, has since become a major production site, with a hundreds of square meters of mother plant and tissue culture laboratory where eight technicians work every day. The company now focuses entirely on cannabis clones, supplying customers in Austria and neighboring countries, often with same-day delivery to selected locations.

Standardized expansion
For Franz Joseph Sima, Fluence’s long-time propagation specialist, the masterclass aimed to show how standard procedures transform the mother and clone phases of cannabis production. “Many producers still have challenges in the expansion phase,” he said. “At Flory Field, these processes have been refined over twenty years. We wanted participants to see how a consistent and commercially viable system works in practice.”

The workshop covered everything from mother plant maintenance and replacement schedules, to light intensity, watering and pest management. The attendees received the full procedure afterwards. “The only condition,” says Franz, “was to be there.”

© Fluence BioengineeringFranz Josef Sima, Cannabis Research & Plant Specialist at Fluence, guiding participants through best practices in mother plant maintenance and clone cutting.

From tissue culture to mother plant
Participants followed the entire production chain, from tissue culture and virus testing in the laboratory, to cutting and preparation of clones. Flowery uses PCR testing to ensure cultivar stability and purity, a practice more common in pharmaceutical or ornamental horticulture than cannabis.

“The contrast was striking,” says Theo. “You have this sterile white lab on one side, and on the other a fully commercial clone factory based on the mother plants. Seeing both under one roof gave people a real sense of scale.”

Opening the doors
One of the main takeaways from the day was the atmosphere of openness. “In the Dutch horticulture industry, growers thrived by visiting each other and sharing knowledge,” says Theo. “In cannabis, everyone tends to close their doors. Events like this are a step to change that.”

The small group format helped. What began as quiet observation soon turned into a back-and-forth of ideas, with growers comparing notes, solving problems, and sharing their methods.

© Fluence BioengineeringAttendees of the Fluence Propagation Masterclass at Flowery Field in Vienna, a meeting of cannabis cultivation professionals from all over Europe.

Interest in the event exceeded expectations, Franz and Theo both say, and Fluence is already considering repeating the format. “We can do another show in the same place, and maybe even one in the US. It’s something that people can clearly see. In cannabis, very few cloning procedures have been proven for a decade or more, so showing something that has stood the test of time makes a big difference.”

For one day, Flowery Field opened its doors, its laboratories and its mother rooms to a small but focused group of professionals. “In a sector where practical knowledge tends to be kept close to the box, that alone was worth a visit,” concludes Theo.

If you are interested in participating in Fluence Masterclass events across Europe, please get in touch (email protected)

For more information:
fluency
https://fluence-led.com/

Continue Reading

Cannabis News

Oregon Officials Seek To Dismiss Psilocybin Access Lawsuit From Homebound Patients

Published

11 hours ago

on

October 26, 2025

By

“Delays in enabling access mean that patients who achieved relief from debilitating anxiety and depression will die in unrelieved suffering.”

Author: Jack Gorsline, Filter

A The legal battle between the state of Oregon and a group of psilocybin boosters has intensified after the state asked for a second time to throw out their lawsuit.

The group originally sued the Oregon Health Authority in 2024 to prevent disabled and dying Oregonians from accessing psilocybin under the state’s Psilocybin Services Act. At the heart of their complaint is that by limiting services to licensed centers and excluding those who cannot travel, the state is violating the Americans with Disabilities Act (ADA).

The plaintiffs, a group of specialty psilocybin suppliers, filed their brief in a federal District Court in Oregon on October 10, challenging the state’s second attempt to dismiss the case.

The Oregon Health Authority (OHA) filed a motion for judgment on the allegations that the plaintiffs lacked standing to state a claim under the ADA. terminally ill and disabled customers.

That motion was followed by a similar motion filed by OHA and a motion to dismiss the case on similar grounds. it was denied in June

Attorneys for the plaintiffs argue that the OHA is trying to avoid reviewing the merits of the case, thereby perpetuating the illegal exclusion of a vulnerable population.

“Plaintiffs’ promoters have complained enough on their behalf and on behalf of their disabled and dying clients,” said Kathryn Tucker of the National Psychedelic Association, one of the attorneys representing them.

He said the state’s position attempts to sidestep the ADA compliance requirement in the operation of the Psilocybin Services Act.

“OHA seeks to avoid compliance with the ADA in the operation of the PSA, as it unlawfully discriminates against Oregonians,” Tucker said. The filter. “Delays in enabling access mean that patients who achieved relief from debilitating anxiety and depression will die in unrelieved suffering.”

The Psilocybin Services Act, passed by Oregon voters in 2020 to establish a legal and regulatory framework to oversee the use of psilocybin, includes legislative findings and detailed statements of goals that indicate the intent to serve populations such as the terminally ill. The plaintiffs in the lawsuit say that the existing rules, which mandate only service at authorized centers, directly contradict that goal.

The plaintiffs are seeking a court order to require OHA to develop a process for domestic service as a reasonable accommodation, and to notify all licensed facilitators that such accommodations are permitted without fear of disciplinary action.

The ongoing litigation highlights the tension between the state’s innovative regulatory framework and the federal Americans with Disabilities Act, which requires public entities to provide reasonable accommodations to ensure services are accessible to people with disabilities. A previous ruling denying OHA’s motion to dismiss suggested that requiring compliance with the ADA—such as access accommodations—would not necessarily compel the state to violate federal law against the distribution of a Schedule I controlled substance.

However, OHA says that current state law, as written, does not provide a legal means to consume psilocybin outside of a licensed service center, and that accommodating home use would violate the statute. This attitude leaves facilitators who want to serve domestic clients in a precarious situation, at risk of losing their licenses or worse if they provide services outside of regulated centers.

Oregon Health Authority officials did not immediately respond The filterrequests for comments.

Meanwhile, the Psilocybin Services Act was intended to help prevent access to a key population in Oregon. The plaintiffs say the delay in providing accessible services has had far-reaching consequences, especially for terminally ill patients who have limited time to potentially transform the rest of their lives.

If the federal court once again denies OHA’s motion to dismiss the case, it will move closer to deciding whether the state must make accommodations for those clients to perform psilocybin services at home. The result could significantly expand access to the state’s pioneering psilocybin program. It may also affect how other states design their programs.

“We hope the Court will decline to avoid merits review, move the case forward, and ensure access to disabled and dying Oregonians, who are among those most likely to benefit from psilocybin services,” Tucker concluded.

This the article Originally published by the author The filteran online magazine that deals with drug use, drug policy and human rights from a harm reduction perspective. Keep the filter on Bluesky, X or Facebookand sign up for their newsletter.

user photo Wikimedia/Staff.

Marijuana Moment is made possible with the help of readers. If you rely on our pro-cannabis journalism to stay informed, consider a monthly Patreon pledge.

Continue Reading

Cannabis News

Local startup expands to 32,000-square-foot cannabis processing facility

Published

1 day ago

on

October 25, 2025

By











Founded in 2018 by six Greek graduates as a CBD company, NOWAVE’s products can be found in 90 percent of New York state’s legal cannabis dispensaries.

“We started with a 300-square-foot space behind a retail store — actually a vape shop,” recalls founder Brian Lane. “((We) started perfecting our gummies, sending them out to vape shops all over the country. The next thing you know, we found ourselves making quite a few gummies. We were self-taught in all of our product types, and now we’ve grown from that 300 square foot space to where we are right now.”

Approximately 100 people work at the Chili facility, producing hemp and CBD products and processing cannabis into edibles, vaping products, and even carbonated beverages containing THC, the psychoactive ingredient in marijuana.

NOWAVE manufactures products for brands including Off Hours, Eaton Botanicals and Weed Water. The company also makes some of the only vegan gummies on the market.

Read more at 13 Yes










Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media